Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00160654
Status:
COMPLETED
Last Update Posted:
2020-08-19
First Post:
2005-09-08
Brief Title:
Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
A Phase IV Open-label Multi-center Community-based Trial in Asia Studying the Safety and Efficacy of Keppra as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy
Status:
COMPLETED
Status Verified Date:
2020-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Community based study assessing safety and efficacy of levetiracetam in partial onset seizures
The optimal dose in daily clinical practice will be used
The optimal dose in daily clinical practice will be used
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None